Company Analysis
Sign in

Radiopharm Theranostics Limited (RADX)

Nasdaq: RADX · Pharmaceutical Preparations · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.7
◀ Past 7.9● Present 4.0▶ Future 5.8
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in June.

The Form 20-F filed Sep 30, 2026 for the period ended Jun 30, 2026 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.

Income statement, by fiscal year, newest first
Fiscal yearFY 2026FY 2025FY 2024FY 2023
Period endingJun 30, 2026Jun 30, 2025Jun 30, 2024Jun 30, 2023
Report filedSep 30, 2026Sep 18, 2025··
Revenue2,767,8883,633,422299,228292,359
Cost of revenue2,504,4993,594,146··
Gross profit263,38939,276299,228292,359
Research and development49,962,89927,515,19423,086,26722,631,509
General and administrative16,215,70214,638,01313,039,24612,231,048
Operating income-56,783,658-38,173,865-47,209,867-34,487,098
Finance costs112,39665,300642,88886,091
Income before income taxes-56,896,054-38,239,165-47,852,755-34,573,189
Income tax expense54,440103,29296,36438,005
Net income-56,950,494-38,342,457-47,949,119-34,611,194
Earnings per share, basic-1.79-1.76-12.41-11.32
Earnings per share, diluted-1.79-1.76-12.41-11.32
Weighted average shares, basic·2,081,058,451386,460,137305,832,976
Weighted average shares, diluted·2,081,058,451386,460,137305,832,976
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldifrs-full:RevenueFromContractsWithCustomers
ifrs-full:Revenue
Cost of revenue what it cost to make or buy what it soldifrs-full:CostOfSales
Gross profit revenue less the cost of what it soldifrs-full:GrossProfit
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfifrs-full:GeneralAndAdministrativeExpense
Operating income profit from running the business, before interest and taxifrs-full:ProfitLossFromOperatingActivities
Finance costs what its borrowing costifrs-full:FinanceCosts
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton RADX · research, not advice